Arch Therapeutics, Inc (OTCQB:ARTH) Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Arch Therapeutics, Inc (OTCQB:ARTH)'s estimated annual revenue is currently $1.7M per year.(i)
  • Arch Therapeutics, Inc (OTCQB:ARTH)'s estimated revenue per employee is $155,000
  • Arch Therapeutics, Inc (OTCQB:ARTH)'s total funding is $20.9M.

Employee Data

  • Arch Therapeutics, Inc (OTCQB:ARTH) has 11 Employees.(i)
  • Arch Therapeutics, Inc (OTCQB:ARTH) grew their employee count by 57% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use. 2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Arch Therapeutics, Inc (OTCQB:ARTH) News

2022-04-13 - Renowned Wound Care Key Opinion Leaders Presented Arch ...

FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and...

2022-03-30 - Arch Therapeutics' AC5® Advanced Wound System to be ...

(OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced...

2022-03-22 - Arch Therapeutics Partners with Centurion Therapeutics to ...

FRAMINGHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding